. 2024 Nov 29;25:977. doi: 10.1186/s12891-024-08113-6

Table 3.

Changes in JSSF hallux total and SAFE-Q scores in the three groups

	40° ≤ HVA < 50° (Preop.)	50° ≤ HVA < 60° (Preop.)	HVA ≥ 60° (Preop.)	40°≤ HVA < 50° (Final follow-up)	50°≤ HVA < 60° (Final follow-up)	HVA ≥ 60° (Final follow-up)
Total JSSF hallux score (median, IQR)	39.3 ± 12.4 (39, 34–46)	38.9 ± 12.7 (39, 35–45)	33.4 ± 15.6 (37, 19–44)	87.2 ± 9.8*** (90, 82–95)	88.7 ± 6.8*** (90, 87–92)	87.6 ± 6.5*** (88, 85–92)
SAFE-Q scores
Pain and pain-related (median, IQR)	48.0 ± 19.4 (46.6, 34.9–62.2)	51.1 ± 25.9 (47.0, 37.1–74.4)	47.4 ± 26.1 (44.4,26.175.0)	86.9 ± 13.0*** (90.3, 83.3–96.0)	89.7 ± 8.8*** (90.6, 87.8–93.3)	82.8 ± 17.2*** (85.4, 75.6–96.1)
Physical functioning (median, IQR)	58.3 ± 21.5 (58.0, 43.2–75.0)	54.0 ± 25.2 (58.0, 29.5–76.7)	52.1 ± 29.3 (63.6, 29.6–77.3)	83.5 ± 15.9*** (88.6, 75.6–97.7)	81.2 ± 14.9*** (87.3, 77.3–92.6)	76.6 ± 18.4** (79.5, 66.0-87.5)
Social functioning (median, IQR)	57.4 ± 27.3 (54.2, 37.5–76.1)	52.8 ± 31.1 (64.6, 33.3–75.0)	52.4 ± 38.1 (62.5, 14.6–89.6)	83.6 ± 16.8*** (89.6, 75.0-100.0)	85.7 ± 18.8*** (91.7, 75.0-100.0)	72.0 ± 32.4 (87.5, 41.7–97.9)
General health and well-being (median, IQR)	52.5 ± 25.1 (50.0, 35.0–70.0)	51.2 ± 30.9 (60.0, 25.0-73.8)	53.3 ± 38.5 (60.0, 14.2–87.5)	86.4 ± 14.2*** (90.0, 75.0-100.0)	82.8 ± 18.1*** (90.0, 80.0–95.0)	78.4 ± 25.1* (90.0, 60.0-97.5)
Shoe-related (median, IQR)	35.6 ± 23.9 (33.3, 23.0–44.0)	35.6 ± 20.7 (37.5, 16.7–50.0)	40.8 ± 28.6 (41.7, 20.9–54.2)	73.2 ± 21.7*** (75.0, 60.4–91.7)	74.2 ± 17.3*** (75.0, 66.7–83.3)	61.8 ± 27.3* (66.7, 50.0-83.3)

40° ≤ HVA < 50°
(Preop.)

50° ≤ HVA < 60°
(Preop.)

HVA ≥ 60°
(Preop.)

40°≤ HVA < 50°
(Final follow-up)

50°≤ HVA < 60°
(Final follow-up)

HVA ≥ 60°
(Final follow-up)

Total JSSF hallux score

(median, IQR)

39.3 ± 12.4

(39, 34–46)

38.9 ± 12.7

(39, 35–45)

33.4 ± 15.6

(37, 19–44)

87.2 ± 9.8***

(90, 82–95)

88.7 ± 6.8***

(90, 87–92)

87.6 ± 6.5***

(88, 85–92)

SAFE-Q scores

Pain and pain-related

(median, IQR)

48.0 ± 19.4

(46.6, 34.9–62.2)

51.1 ± 25.9

(47.0, 37.1–74.4)

47.4 ± 26.1

(44.4,26.175.0)

86.9 ± 13.0***

(90.3, 83.3–96.0)

89.7 ± 8.8***

(90.6, 87.8–93.3)

82.8 ± 17.2***

(85.4, 75.6–96.1)

Physical functioning

(median, IQR)

58.3 ± 21.5

(58.0, 43.2–75.0)

54.0 ± 25.2

(58.0, 29.5–76.7)

52.1 ± 29.3

(63.6, 29.6–77.3)

83.5 ± 15.9***

(88.6, 75.6–97.7)

81.2 ± 14.9***

(87.3, 77.3–92.6)

76.6 ± 18.4**

(79.5, 66.0-87.5)

Social functioning

(median, IQR)

57.4 ± 27.3

(54.2, 37.5–76.1)

52.8 ± 31.1

(64.6, 33.3–75.0)

52.4 ± 38.1

(62.5, 14.6–89.6)

83.6 ± 16.8***

(89.6, 75.0-100.0)

85.7 ± 18.8***

(91.7, 75.0-100.0)

72.0 ± 32.4

(87.5, 41.7–97.9)

General health and well-being

(median, IQR)

52.5 ± 25.1

(50.0, 35.0–70.0)

51.2 ± 30.9

(60.0, 25.0-73.8)

53.3 ± 38.5

(60.0, 14.2–87.5)

86.4 ± 14.2***

(90.0, 75.0-100.0)

82.8 ± 18.1***

(90.0, 80.0–95.0)

78.4 ± 25.1*

(90.0, 60.0-97.5)

Shoe-related

(median, IQR)

35.6 ± 23.9

(33.3, 23.0–44.0)

35.6 ± 20.7

(37.5, 16.7–50.0)

40.8 ± 28.6

(41.7, 20.9–54.2)

73.2 ± 21.7***

(75.0, 60.4–91.7)

74.2 ± 17.3***

(75.0, 66.7–83.3)

61.8 ± 27.3*

(66.7, 50.0-83.3)

Data are presented as mean ± SD unless otherwise noted. Analysis of variance (ANOVA) was used to test for differences between the three groups (p < 0.05). Differences between pre- and postoperative data were assessed using the Mann–Whitney U-test (* p < 0.05, ** p < 0.01, *** p < 0.001)

HVA; hallux valgus angle, JSSF; Japanese Society for Surgery of the Foot, SAFE-Q; self-administered foot evaluation questionnaire, IQR; Interquartile Range